Trails Edge Capital Partners, LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Trails Edge Capital Partners, LP disclosed 35 US equity positions worth $629.9m in its Q2 2026 13F filing. The largest position was LB PHARMACEUTICALS INC at 7.8% of the reported book, followed by NRIX and IMCR. Against the Q1 2026 filing, it opened 13 new positions, added to 10 and reduced 6 among the top 35 holdings.
What did Trails Edge Capital Partners, LP own in Q2 2026? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | LB PHARMACEUTICALS INC | 7.8% | $49.4m | 1,523,022 | 15% | added | |
| 2 | NRIX NURIX THERAPEUTICS INC | Healthcare | 6.1% | $38.2m | 1,573,220 | -10% | reduced |
| 3 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 5.4% | $33.8m | 1,063,234 | 56% | added |
| 4 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 4.8% | $30.5m | 1,514,000 | – | new | |
| 5 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 4.7% | $29.6m | 2,227,917 | 71% | added |
| 6 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 4.7% | $29.3m | 512,000 | – | new |
| 7 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 4.6% | $29.0m | 2,001,282 | 135% | added |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.2% | $26.6m | 440,000 | 0% | held |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 4.2% | $26.1m | 223,312 | -33% | reduced |
| 10 | INSM INSMED INC | Healthcare | 3.9% | $24.6m | 230,331 | – | new |
| 11 | CYTK CYTOKINETICS INC | Healthcare | 3.9% | $24.5m | 288,089 | -4% | reduced |
| 12 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.9% | $24.3m | 1,110,000 | 58% | added |
| 13 | NGNE NEUROGENE INC | 3.6% | $22.5m | 714,885 | -9% | reduced | |
| 14 | KAILERA THERAPEUTICS INC | 3.4% | $21.7m | 984,786 | – | new | |
| 15 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.4% | $21.7m | 115,750 | -53% | reduced |
| 16 | IKT INHIBIKASE THERAPEUTICS INC | 2.9% | $18.4m | 9,051,318 | 12% | added | |
| 17 | INCY INCYTE CORP | Healthcare | 2.8% | $17.6m | 155,000 | – | new |
| 18 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.6% | $16.5m | 891,881 | – | new |
| 19 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.3% | $14.6m | 750,000 | – | new |
| 20 | FTH FAETH THERAPEUTICS INC | 2.0% | $12.9m | 515,335 | 312% | added | |
| 21 | XFOR X4 PHARMACEUTICALS INC | 1.9% | $12.0m | 2,571,478 | 0% | held | |
| 22 | IRD OPUS GENETICS INC | 1.8% | $11.3m | 2,743,658 | 449% | added | |
| 23 | SOL-GEL TECHNOLOGIES LTD | 1.6% | $10.3m | 139,445 | 63% | added | |
| 24 | AURA AURA BIOSCIENCES INC | 1.6% | $10.2m | 1,443,333 | – | new | |
| 25 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.6% | $10.1m | 4,134,969 | 69% | added |
| 26 | IVA INVENTIVA SA | 1.6% | $10.0m | 2,657,997 | 0% | held | |
| 27 | CAMP CAMP4 THERAPEUTICS CORP | 1.3% | $8.4m | 1,932,937 | -0% | held | |
| 28 | ALT ALTIMMUNE INC | Healthcare | 1.3% | $8.1m | 2,660,000 | – | new |
| 29 | NERV MINERVA NEUROSCIENCES INC | 1.3% | $7.9m | 1,419,000 | 0% | held | |
| 30 | PROMIS NEUROSCIENCES INC | 1.2% | $7.3m | 557,103 | 0% | held | |
| 31 | OKUR ONKURE THERAPEUTICS INC | 1.0% | $6.6m | 1,438,456 | – | new | |
| 32 | FBRX FORTE BIOSCIENCES INC | 0.9% | $5.8m | 273,181 | – | new | |
| 33 | RESEARCH ALLIANCE CORP III | 0.8% | $5.3m | 500,000 | – | new | |
| 34 | VTVT VTV THERAPEUTICS INC | 0.5% | $3.2m | 85,192 | -39% | reduced | |
| 35 | IMA IMAGENEBIO INC | 0.3% | $1.7m | 282,004 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.